Adding AZD1390 to Radiation for New Brain Tumors
Part of Cancer clinical trials.
This trial tests adding a new drug called AZD1390 to standard radiation therapy for children and young adults with certain aggressive brain tumors. The goal is to see if the combination is safe and works better than radiation alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 year and 22 years old, depending on the part of the study.
- You must have a newly diagnosed high-grade glioma, diffuse midline glioma, or DIPG that has not been treated before (except surgery or steroids).
- You must be able to swallow whole tablets (not through a feeding tube).
- You must have good kidney, liver, and bone marrow function (tests will be done to check).
- You cannot have certain eye problems, prior radiation, or strong drug interactions with this medicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
This trial tests adding atovaquone to standard radiation therapy for children with aggressive brain tumors like high-grade glioma (a fast-growing brain cancer) or medulloblastoma. The goal is to see if this drug, which targets energy production in cancer cells, can make radiation work better.
This trial studies whether adding selinexor to standard radiation can improve outcomes for children and young teens with certain newly diagnosed high-grade brain tumors (including DIPG). It’s designed for specific tumor types and genetic markers, and people must be able to start treatment soon after diagnosis.
This trial tests a new drug called ADI-PEG 20 combined with standard treatments (temozolomide and radiation) for children and young adults with newly diagnosed high-grade glioma. It aims to see if this combination is safe and effective.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
This trial tests a new oral drug called XRD-0394 given together with radiation therapy for people with high-grade glioma, a type of aggressive brain tumor. The goal is to see if adding this drug makes radiation more effective.
Hear when a new Childhood Astrocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.